Role of Adjunctive Use of Intravitreal Bevacizumab for Severe Proliferative Diabetic Retinopathy before Vitrectomy
/ 0
- Details
- Category: Vol. 79, June 2011
- Hits: 624
Role of Adjunctive Use of Intravitreal Bevacizumab for Severe Proliferative Diabetic Retinopathy before Vitrectomy,AMR KHAFAGY
Abstract
Purpose: To evaluate the safety and efficacy of intravitreal injection of bevacizumab advanced to vitrectomy for severe proliferative diabetic retinopathy.
Methods: This is a prospective study in which, Ten eyes of ten patients with an average age 54.1±6.5 years (45-64 years old) complaining of severe proliferative diabetic retin-opathy were investigated. An intravitreal injection of 1.25mg bevacizumab was performed 3-10 days prior to planned vitrectomy. A written informed consent was obtained from all patients. All of them were completely evaluated in the out patient department. Fluorescein angiography was advised to every patient.
Results: All cases showed minimum bleeding during surgical dissection of fibro-vascular membrane and less post-operative complications were observed. Two eyes receiving bevacizumab 3-10 days before the surgery showed strong fibrosis and adhesion of fibro-vascular membrane, resulted in some surgical complications. The cases having intravitreal bevacizumab for shorter time before vitrectomy did not show extensive fibrosis.
Conclusion: Intravitreal bevacizumab was safe and effec-tive in pre treatment of proliferative diabetic retinopathy prior to vitrectomy. It can induce effective regression of retinal neovascularization and rapid clearance of vitreous hemorrhage.